Biocare Medical, Concord, Calif, and Bethyl Laboratories, Montgomery, Texas, have released a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody, for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. TIGIT plays an important role in transplantation tolerance and tumor immune surveillance. Several studies indicate that TIGIT exhibits a synergistic function with the PD-1/PD-L1 pathway in the inhibition of T cell proliferation. The use of TIGIT, in conjunction with other checkpoint receptors, such as PD-1, has shown to be a promising marker for immunotherapy. “We are excited for the release of an IVD grade TIGIT [BL074F] antibody for clinical application; the Bethyl clone [BLR047F] has been shown to display high sensitivity and specificity based on our internal research,” says Jason Ramos, PhD, vice president Reagent Research and Development at Biocare Medical. “We believe that our new TIGIT IVD antibody will be a cost-effective IHC solution to the pharmaceutical and biotech research institutions requiring an IVD grade quality in early-stage research and companion diagnostics development.” TIGIT [BLR047F] is an IVD antibody available in a concentrate format to support titration by end-users as well as a ready-to-use predilute format. TIGIT [BLR047F] antibody is commercially available for immediate sale within the domestic United States and European Union. For additional information, visit Bethyl Laboratories and Biocare Medical.
